The US Food and Drug Administration (FDA) has approved Austedo XR (deutetrabenazine) extended-release tablets, a new once-daily formulation indicated in adults for tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD).
Developed by Israeli generics giant Teva Pharmaceutical Industries (NYSE/TASE: TEVA), Austedo XR is an additional formulation of the currently marketed twice-daily Austedo, which was approved by the FDA in 2017.
“The approval of Austedo XR is a reflection of our ongoing innovation for people living with TD and HD chorea,” said Dr Eric Hughes, executive vice president of R&D and chief medical Officer at Teva. “For some patients living with TD and HD, treatment adherence can be a challenge that this new once-daily dosing option can help to address,” he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze